Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In “Molecular Therapy,” a team led by Armin Rehm at the Max Delbrück Center presents an improved immunotherapy that recognizes two distinct features of malignant cells to destroy the cancer more effectively.

New preclinical research suggests that bowel preparation procedures for colonoscopies may temporarily alter gut balance, culminating in unappreciated effects in patients with compromised gastrointestinal health.

City of Hope®, a leading cancer research and treatment organization, and Cellares, the first Integrated Development and Manufacturing Organization (IDMO), announce a collaboration focused on the City of Hope-developed IL13RA2-EGFR CAR T cell program addressing glioblastoma multiforme. City of Hope licensed this technology to Mustang Bio Inc. Under the collaboration, City of Hope will evaluate Cellares’ Cell Shuttle™ automated manufacturing platform and Cell Q™ automated quality control system to enable reliable, high-throughput manufacturing and quality control of its CARpool program. By engaging at the preclinical stage, the collaboration will establish platform processes and analytics purpose-built for solid tumor CAR T programs, accelerating advancement into clinical trials while enabling scalable manufacturing to meet global patient demand.

The partnership enables Fox Chase to become the first NCI-designated Comprehensive Cancer Center to implement clinical testing utilizing Arima's 3D-genomics technology in multiple tumor types as part of a standard protocol.